2023
POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS
Coates L, Strober B, Yu J, Leibowitz E, Rowland K, Kollmeier A, Miller M, Wang Y, LI S, Chakravarty S, Chan D, Shawi M, Yang Y, Lebwohl M, Rahman P. POS1538 SAFETY OF GUSELKUMAB ACROSS DIVERSE PATIENT SUBGROUPS WITH PSORIATIC DISEASE: AN INTEGRATED ANALYSIS OF 11 PHASE 2/3 CLINICAL STUDIES IN PSORIASIS AND PSORIATIC ARTHRITIS. 2023, 1134-1135. DOI: 10.1136/annrheumdis-2023-eular.1917.Peer-Reviewed Original Research
2021
27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial
Puig L, Strober B, Tsai T, Thaçi D, Gooderham M, Miller M, Yang Y, You Y, Shen Y, Blauvelt A. 27596 Improvement in absolute psoriasis area and severity index through 5 years of continuous treatment with guselkumab in the VOYAGE 1 trial. Journal Of The American Academy Of Dermatology 2021, 85: ab154. DOI: 10.1016/j.jaad.2021.06.629.Peer-Reviewed Original Research